1. Home
  2. PJT vs CPRX Comparison

PJT vs CPRX Comparison

Compare PJT & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PJT Partners Inc.

PJT

PJT Partners Inc.

HOLD

Current Price

$155.10

Market Cap

3.9B

Sector

Finance

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.39

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PJT
CPRX
Founded
2014
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.4B
IPO Year
2015
2006

Fundamental Metrics

Financial Performance
Metric
PJT
CPRX
Price
$155.10
$31.39
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$178.50
$35.00
AVG Volume (30 Days)
297.1K
1.7M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
0.66%
N/A
EPS Growth
N/A
28.24
EPS
N/A
0.50
Revenue
$1,713,671,000.00
$119,072,803.00
Revenue This Year
$11.12
$9.20
Revenue Next Year
$9.98
$10.51
P/E Ratio
$23.03
$62.70
Revenue Growth
14.77
16.39
52 Week Low
$127.73
$19.05
52 Week High
$195.62
$32.56

Technical Indicators

Market Signals
Indicator
PJT
CPRX
Relative Strength Index (RSI) 49.71 72.89
Support Level $148.69 $31.25
Resistance Level $163.37 $32.56
Average True Range (ATR) 5.45 0.04
MACD -0.23 -0.15
Stochastic Oscillator 37.27 100.00

Price Performance

Historical Comparison
PJT
CPRX

About PJT PJT Partners Inc.

PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: